Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Chinese subjects with moderate to severe plaque psoriasis
NCT05108766Phase 3Completed
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tildrakizumab in plaque psoriasis, sponsored by Shenzhen Kangzhe Pharmaceutical Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
tildrakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05108766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108766.